Screening for Age-Related Macular Degeneration: A Cost-Effectiveness Evaluation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F24%3A00376435" target="_blank" >RIV/68407700:21460/24:00376435 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/978-3-031-64636-2_3" target="_blank" >https://doi.org/10.1007/978-3-031-64636-2_3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-031-64636-2_3" target="_blank" >10.1007/978-3-031-64636-2_3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Screening for Age-Related Macular Degeneration: A Cost-Effectiveness Evaluation

Popis výsledku v původním jazyce

Age-related macular degeneration (AMD) is the leading cause of blindness in people over the age of 50 in developed countries. Due to its slow progression and unrecorded subjective symptoms, the cost of treating advanced forms of the disease is high each year. The aim of this study is to perform a cost-utility analysis of the introduction of a screening program for the population over 50 years of age for the early detection of AMD in the Czech Republic. A Markov model was constructed for evaluation in a time horizon of 40 years. The cost-utility analysis was performed at the end of the study and the results are presented in incremental cost-utility ratios (ICUR) using quality-adjusted life years. Uncertainty was assessed using one-way sensitivity analysis. The cumulative cost of the strategy without screening is CZK 7,722,485 and the cumulative cost of the strategy with screening is CZK 2,077,740. The cumulative utility of the non-screening strategy is 14.39 QALYs and the cumulative utility of the screening strategy is 21.46 QALYs. The ICUR is -798,921 CZK/QALY. The results of this study suggest that a screening strategy is cost-effective.

Název v anglickém jazyce

Screening for Age-Related Macular Degeneration: A Cost-Effectiveness Evaluation

Popis výsledku anglicky

Age-related macular degeneration (AMD) is the leading cause of blindness in people over the age of 50 in developed countries. Due to its slow progression and unrecorded subjective symptoms, the cost of treating advanced forms of the disease is high each year. The aim of this study is to perform a cost-utility analysis of the introduction of a screening program for the population over 50 years of age for the early detection of AMD in the Czech Republic. A Markov model was constructed for evaluation in a time horizon of 40 years. The cost-utility analysis was performed at the end of the study and the results are presented in incremental cost-utility ratios (ICUR) using quality-adjusted life years. Uncertainty was assessed using one-way sensitivity analysis. The cumulative cost of the strategy without screening is CZK 7,722,485 and the cumulative cost of the strategy with screening is CZK 2,077,740. The cumulative utility of the non-screening strategy is 14.39 QALYs and the cumulative utility of the screening strategy is 21.46 QALYs. The ICUR is -798,921 CZK/QALY. The results of this study suggest that a screening strategy is cost-effective.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

50602 - Public administration

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Lecture Notes in Computer Science

ISBN

978-3-031-64635-5

ISSN

2366-6323

e-ISSN

1611-3349

Počet stran výsledku

11

Strana od-do

31-41

Název nakladatele

Springer

Místo vydání

Cham

Místo konání akce

Gran Canaria

Datum konání akce

15. 7. 2024

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

001308622700003